Skip to main content

Business Wire India

 

Clinical courses

 

Clinical research courses

  • (Business Wire India); Biocon Ltd, Asia's premier biopharmaceuticals company, today announced that its Contract Research subsidiary Syngene International Ltd (“Syngene”) has filed the Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) on April 22, 2015, seeking approval for an Initial Public Offering (IPO). This is an offer for sale (OFS) by Biocon of a part of its shareholding in Syngene. Biocon along with its subsidiary Biocon Research Limited (BRL) currently holds an 84.5% equity stake in Syngene.

  • Merck, a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials, in collaboration with Maharashtra University of Health Sciences and Directorate of Medical Education & Research is introducing European Accredited Clinical Diabetes management for more than 5000 medical students in 18 medical colleges of Maharashtra University as part of Merck Capacity Advancement Program (CAP) in Asia.

  • (Business Wire India); Kiran Mazumdar-Shaw, Chairperson of Asia's premier biopharmaceutical enterprise Biocon Ltd., has been honoured by Federation University Australia (Fed Uni) by dedicating a road at the University’s Mt Helen Campus to her as ‘Mazumdar Drive’. She has also been appointed as an Ambassador of the University for a three-year term.

    (adsbygoogle = window.adsbygoogle || []).push({});
  • (Business Wire India); India has a very unique talent pool of an estimated 2-3 million educated disabled. What makes them so unique? The educated disabled have demonstrated tremendous resilience and have been toughened by the day to day challenges of inadequate school facilities, lack of accommodating transport infrastructure and yet have graduated from high schools and colleges. This segment of society reflects an enormous “can-do” attitude and is equipped with tremendous staying power which corporate India can leverage.

    (adsbygoogle = window.adsbygoogle || []).push({});
  • The skewed ratio of hazardous waste generated daily to innovations in hazardous waste management, points to a large unmet need for novel hazardous waste management technologies and processes. Apart from the rising volumes of hazardous waste, technology development in this space will also get a huge boost from the treaties signed by various countries for stopping transboundary waste shipping and public opposition to landfills.

  • (Business Wire India); Tata Capital, the financial services arm of the Tata Group, as part of its Do Right initiative, concluded a first-of-its-kind Survey to identify the major challenges facing our country today. The “Tata Capital India4India” Survey was conducted online on the website – doright.in & saw voting from more than 5000 respondents across the country. The top five challenges that emerged as the most concerning for the Indian public were Basic Healthcare, Illiteracy, Child Rights, Women Empowerment and Food Scarcity.

  • (17th November, 2014; Business Wire India); We are all aware of the dangers of a heart attack, few are aware of an equally dangerous condition called “Leg Attacks”. Quite similar to heart attacks, leg attacks occur when there are blockages in the blood vessels of the leg. This condition is exacerbated in Diabetics, those aged above 50 and smokers who are at a higher risk of developing blockages or peripheral vascular diseases. Leg attack is one of the extreme conditions arising from blockages in the vessels of the limbs which can lead to non healing ulcer even limb amputation. Most doctors agree that despite the severity of leg attacks, most cases remain undiagnosed till the last stage due to a lack of awareness of the disease and its symptoms.

  • (6th November, 2014; Business Wire India); Asia’s leading Discovery Research and Development organization, GVK BIO, announced the signing of a definitive agreement to acquire Vanta Bioscience, a full service preclinical GLP toxicology and safety assessment contract research organization operating out of Chennai, India.

  • (3rd November, 2014; Business Wire India); Biocon Ltd, Asia's premier biopharmaceuticals company, and U.S.-based CytoSorbents Corporation (OTCQB: CTSO) announced today that they have expanded the scope of their strategic partnership for CytoSorbents’ CytoSorb® cytokine reduction therapy to treat patients experiencing severe whole body inflammation, often called a Systemic Inflammatory Response Syndrome (SIRS).  SIRS is caused by a wide range of life-threatening conditions seen in the intensive care unit and can also be caused by surgical interventions, particularly cardiac surgery.

    (adsbygoogle = window.adsbygoogle || []).push({});
Subscribe to Business Wire India